Literature DB >> 26690268

Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study.

Nima Kokabi1, Minzhi Xing2, Richard Duszak1, Richard Duszak1, David H Howard3, Kimberly E Applegate1, Juan C Camacho1, Hyun S Kim2,4.   

Abstract

AIM: To investigate outcomes in unresectable hepatocellular carcinoma (HCC) patients stratified by sociodemographic and clinical factors in a population study. MATERIALS &
METHODS: Surveillance, Epidemiology and End Results (SEER) database was used to identify patients diagnosed in 2000-2011. Overall survival (OS) was stratified using patient sociodemographic characteristics and American Joint Commission on Cancer (AJCC) staging. Log-rank test and Cox proportional hazard models were used to identify prognostic factors of OS.
RESULTS: In patients with AJCC stage I and II unresectable HCC, prolonged OS was correlated with being married, younger age, ethnicity, geographic location, living in large urban areas, being insured and higher income and education levels.
CONCLUSION: In AJCC stage I and II unresectable HCC patients with favorable sociodemographic factors, prolonged OS maybe in part related to better access to cancer-directed therapy.

Entities:  

Keywords:  HCC; SEER; access to care; cancer-directed therapy; demographic; disparity; socioeconomic; survival; unresectable

Mesh:

Year:  2015        PMID: 26690268     DOI: 10.2217/fon.15.242

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

1.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

2.  The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population.

Authors:  Patricia D Jones; Carlos Diaz; Danlu Wang; Joselin Gonzalez-Diaz; Paul Martin; Erin Kobetz
Journal:  Dig Dis Sci       Date:  2017-12-23       Impact factor: 3.199

3.  Impact of Socioeconomic Factors on Prognosis and Clinical Management in Patients with Hepatocellular Carcinoma.

Authors:  Bing-Bing Su; Bao-Huan Zhou; Dou-Sheng Bai; Jian-Jun Qian; Chi Zhang; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

4.  The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center.

Authors:  Laura A Evans; Ronald Go; Rahma Warsame; Bharat Nandakumar; Francis K Buadi; Angela Dispenzieri; David Dingli; Martha Q Lacy; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Eli Muchtar; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Mustaqeem Siddiqui; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Shaji Kumar; Wilson I Gonsalves
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-02-17

5.  Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012.

Authors:  Shuncong Wang; Huanhuan Sun; Zhinan Xie; Jie Li; Guobin Hong; Dan Li; Saradhi Mallampati; Xiuling Zhou; Cuiling Zhou; Hongyu Zhang; Zhibin Cheng; Hong Shan; Haiqing Ma
Journal:  Oncotarget       Date:  2016-09-13

6.  Lower Education and Household Income Contribute to Advanced Disease, Less Treatment Received and Poorer Prognosis in Patients with Hepatocellular Carcinoma.

Authors:  Yuan Shen; Hui Guo; Tao Wu; Qiang Lu; Ke-Jun Nan; Yi Lv; Xu-Feng Zhang
Journal:  J Cancer       Date:  2017-09-02       Impact factor: 4.207

Review 7.  Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma.

Authors:  Ramesh P Thylur; Sanjit K Roy; Anju Shrivastava; Thomas A LaVeist; Sharmila Shankar; Rakesh K Srivastava
Journal:  JGH Open       Date:  2020-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.